NCT01487135View on ClinicalTrials.gov

Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Healthy SubjectsCardiac Repolarization
Interventions
DRUG

EVP-6124

A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.

DRUG

Placebo

Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.

DRUG

Moxifloxacin

A moxifloxacin 400 mg tablet administered orally on Day 1

Sponsors
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

FORUM Pharmaceuticals Inc

INDUSTRY